fluoroestradiol f 18

Fluoroestradiol F 18 is a radiopharmaceutical and synthetic estrogen analog used as a radioactive diagnostic agent for positron emission tomography (PET) imaging. It is indicated to detect estrogen receptor-positive (ER+) lesions in patients with recurrent or metastatic breast cancer. The drug binds with high affinity to estrogen receptors (ER), allowing visualization of ER expression in tumors and assessment of heterogeneity across metastases without the need for multiple biopsies. After intravenous administration, it distributes primarily to the hepatobiliary system and other organs such as intestines, heart wall, kidney, uterus, and bladder. Fluoroestradiol F 18 is metabolized in the liver and excreted via gallbladder and kidneys[1][2][3][4][7]. The drug was first approved by the FDA in May 2020 under the brand name Cerianna[3].

Brand names

Cerianna

Other names

[18F]16α-Fluoroestra-1,3,5(10)-triene-3,17β-diolfluoroestradiol fluorine 18